Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INCLUSION: Lenacapavir PrEP in Latine GBM and TGW
NCT07218211Phase 4Recruiting
- Sponsor
- Duke University
- Start
- Jan 2026
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of lenacapavir in human immunodeficiency virus infection (HIV), sponsored by Duke University. Started Jan 2026; status: recruiting.
02
Drugs
lenacapavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT07218211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07218211.